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OBJECTIVE
In the ACCORD trial, intensive treatment of patients with type 2 diabetes and high
cardiovascular (CV) risk was associated with higher all-cause and CV mortality.
Post hoc analyses have failed to implicate rapid reduction of glucose, hypoglyce-
mia, or specific drugs as the causes of this finding.We hypothesized that exposure
to injected insulin was quantitatively associated with increased CV mortality.
RESEARCH DESIGN AND METHODS
We examined insulin exposure data from 10,163 participants with a mean follow-
up of 5 years. Using Cox proportional hazards models, we explored associations
between CVmortality and total, basal, and prandial insulin dose over time, adjust-
ing for both baseline and on-treatment covariates including randomized interven-
tion assignment.
RESULTS
More participants allocated to intensive treatment (79%) than standard treat-
ment (62%) were ever prescribed insulin in ACCORD, with a higher mean updated
total daily dose (0.41 vs. 0.30 units/kg) (P < 0.001). Before adjustment for cova-
riates, higher insulin dose was associated with increased risk of CV death (hazard
ratios [HRs] per 1 unit/kg/day 1.83 [1.45, 2.31], 2.29 [1.62, 3.23], and 3.36 [2.00,
5.66] for total, basal, and prandial insulin, respectively). However, after adjust-
ment for baseline covariates, no significant association of insulin dose with CV
death remained. Moreover, further adjustment for severe hypoglycemia, weight
change, attained A1C, and randomized treatment assignment did not materially
alter this observation.
CONCLUSIONS
These analyses provide no support for the hypothesis that insulin dose contrib-
uted to CV mortality in ACCORD.
Epidemiological analyses and some interventional studies suggest that attainment
of lower mean levels of A1C is associated with reduced risk of cardiovascular (CV)
death as well as other medical outcomes (1,2). Other epidemiological data, how-
ever, suggest that optimal A1C may be approximately 7.5% (58 mmol/mol) and
indicate higher mortality in those with both lower and higher A1C levels (3).
Recent randomized studies have failed to demonstrate reductions of all-cause or
CV mortality accompanying intensive glucose-lowering therapy in people with type
2 diabetes (4–7). In the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial, both all-cause and CV mortality were higher with intensive glycemic
treatment (4,5). This observation has prompted reevaluation of potential risks as-
sociated with seeking intensive glycemic treatment goals.
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Further analyses from ACCORD have
failed to establish that differences in the
rate of reduction of A1C to near-normal
levels, severe hypoglycemia, or weight
gain explain the increased death rate
among intensively treated subjects
(2,4,8–11). Instead, Riddle et al. (12)
found that the excess mortality in
ACCORD occurred among participants
who were randomized to intensive
treatment but were unable to reduce
their average A1C levels during the ini-
tial year of follow-up to ,7.0% (53
mmol/mol). Also, rates of severe hypo-
glycemia were elevated at higher levels
of A1C during treatment in both the in-
tensively treated and standard treat-
ment groups (11).
Based on these findings, it seems pos-
sible that progressively greater use of
insulin for treating persistently high
A1C might have contributed to in-
creased CV mortality in ACCORD. This
possibility is supported by previous epi-
demiological analyses showing an asso-
ciation between insulin therapy and
mortality (3,13–15). In the Helsinki Po-
licemen Study, hyperinsulinemiawas as-
sociated with increased all-cause and CV
mortality independent of other risk fac-
tors (16). Furthermore, actions of insulin
at the cellular level may favor vascular
changes leading to adverse CV out-
comes (17,18). It is therefore plausible
that intensive treatment with increas-
ingly higher doses of exogenous insulin
fails to normalize glucose levels and yet
causes adverse effects in severely insulin-
resistant individuals. This hypothesis
could be tested with ACCORD data be-
cause prescribed adjustments of glucose-
lowering medications, including insulin,
were recorded for all participants. For
clarification of the relationships of exog-
enous insulin dose, glycemic control,
and CV mortality, we performed post
hoc analyses of ACCORD baseline and
follow-up data.
RESEARCH DESIGN AND METHODS
ACCORD Study Design
The rationale, study design, and entry
criteria for the ACCORD trial have pre-
viously been described (19–21). The
ACCORD trial was conducted in the
U.S. and Canada at 77 clinical sites. Be-
tween January 2001 and October 2005,
10,251 participants with type 2 diabetes
and either a prior CV event or other ev-
idence of high CV disease risk were
enrolled. Participants were randomly as-
signed to either a standard glycemic
treatment strategy (n = 5,123) with the
aim of keeping A1C between 7.0% (53
mmol/mol) and 7.9% (63 mmol/mol) or
an intensive strategy (n = 5,128) with the
aimofachievingA1C,6.0%(42mmol/mol).
In addition, as described in detail else-
where (19–21), participants were also al-
located to interventions in the blood
pressure and lipid-lowering studies that
were also part of ACCORD. The primary
end point of ACCORD was a composite
of CV mortality, nonfatal myocardial in-
farction, or nonfatal stroke. All-cause
mortality was a predefined secondary
end point.
In February 2008, the intensive glyce-
mic treatment strategywas stopped ow-
ing to an increase in all-cause mortality,
and intensive participants were transi-
tioned to standard therapy. The data
set used for the present analyses in-
cludes 10,163 of the 10,251 randomized
participants. The remaining 88 partici-
pants were excluded because they did
not have follow-up data for medications
or A1C values.
Participants visited clinical sites every
2 to 4 months. At the 4-month intervals,
they were asked about hypoglycemia
and other medical events, were
weighed, and had blood collected for
A1C measurements. Follow-up visits
took place between January 2001 and
June 2009, with a mean of 4.97 years
of follow-up per participant, represent-
ing 50,464 participant-years. Ana-
lyses were performed using all ACCORD
follow-up until the closeout visits, which
began in the spring of 2009.
Definition of Covariates and
Exposures
Baseline Covariates
Baseline participant covariates included
those used by Riddle et al. (12) in their pre-
dictive models for ACCORD mortality.
These covariates are listed in Table 1.
Time-Varying Medication Exposure
We defined exposure to insulin in terms
of the updated, average daily recom-
mended (prescribed) dose in units per
kilogram of body weight, calculated
in a cumulative manner and updated
each time a dose changed (the cumula-
tive daily dose over time divided by the
number of days of follow-up). If the in-
formation was missing at a particular
visit for participants who were known
to have recently been on insulin, then
they were deemed to be on the same
dose of insulin as their last recorded
dose. The calculation of insulin dose in-
cluded data from randomization until
CV death or the end of follow-up. Up-
dated, average measures for three dif-
ferent characterizations of insulin,
including total insulin, basal insulin (in-
cluding the component of premixed in-
sulin), and bolus insulin (including the
component of premixed insulin), were
the main predictors of interest. Basal
insulins used included glargine, detemir,
and human NPH; bolus insulins included
aspart, glulisine, lispro, and human reg-
ular insulin.
Other Time-Varying Covariates
Updated, average A1C during follow-up
was calculated in a cumulative manner
throughout follow-up and updated each
time a new value was obtained (i.e., the
newly obtainedA1Cwas allocated toeach
follow-up day since the previously ob-
tained A1C, and the mean of these values
over all follow-up days was obtained).
Weight change frombaselinewas defined
as a time-varying covariate. Both have
previously been described (12).
Statistical Analyses
Means or percentages of potential con-
founding variables at baseline were
computed. Baseline characteristics of
participants who were prescribed any
type of insulin therapy during the study
were compared with those who were
never prescribed insulin, stratified by
treatment assignment, with x2 tests for
categorical variables and two-sample
t tests for continuous variables (Supple-
mentary Tables 1 and 2).
Unadjusted relationships of baseline
factors with CV mortality were exam-
ined to identify potentially confounding
variables using Cox proportional hazards
models (Table 1). Hazard ratio (HR) esti-
mates and their 95% CIs were computed
and Wald tests were performed. For se-
lection of baseline covariates for inclu-
sion, participant covariates and clinical
site characteristics were used in model
selection procedures; stepwise, back-
ward, and forward selection approaches
resulted in the same models. The signif-
icance level for entering and remov-
ing a covariate from the model was
0.05. Note that the level of collinearity
for all the baseline factors was in-
spected and all variance inflation factor
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Table 1—Baseline characteristics of the study population and of the study sites at which the participants were enrolled, with
univariate (unadjusted) HRs for CV mortality
Baseline characteristic Value HR (95% CI) P Overall P
Age (years) 62.2 6 6.8 1.07 (1.05, 1.08) ,0.001
Female 3,906 (38.4) 0.57 (0.44, 0.73) ,0.001
Race/ethnicity 0.097
African American 1,927 (19.0) 0.90 (0.68, 1.19) 0.466
Hispanic 727 (7.2) 0.83 (0.53, 1.30) 0.424
Other 1,110 (10.9) 0.59 (0.39, 0.90) 0.015
Non-Hispanic white 6,399 (63.0) 1
Diabetes duration (years) ,0.001
#5 2,988 (29.4) 1
6–10 2,914 (28.7) 0.85 (0.62, 1.17) 0.316
11–15 1,942 (19.1) 0.98 (0.70, 1.37) 0.905
$16 2,319 (22.8) 1.68 (1.27, 2.23) ,0.001
History of CV disease (yes vs. no) 3,576 (35.2) 3.11 (2.49, 3.88) ,0.001
Prior myocardial infarction (yes vs. no) 471 (4.6) 2.87 (2.05, 4.00) ,0.001
Heart failure/congestive heart failure (yes vs. no) 491 (4.9) 4.57 (3.43, 6.09) ,0.001
Retinal surgery (yes vs. no) 890 (8.8) 1.56 (1.13, 2.15) 0.007
Amputation (yes vs. no) 184 (1.8) 3.32 (2.06, 5.33) ,0.001
Education ,0.001
Less than high school 1,501 (14.8) 2.30 (1.65, 3.21) ,0.001
High school graduate 2,682 (26.4) 1.39 (1.00, 1.93) 0.048
Some college 3,330 (32.8) 1.34 (0.98, 1.84) 0.068
College graduate or more 2,643 (26.0) 1
Smoking 0.001
Former 4,492 (44.2) 1.56 (1.23, 1.98) ,0.001
Current 1,411 (13.9) 1.30 (0.92, 1.85) 0.140
Never 4,260 (41.9) 1
Alcohol use 0.348
1–6 drinks/week 1,963 (19.3) 0.82 (0.61, 1.09) 0.171
$7 drinks/week 470 (4.6) 1.09 (0.67, 1.78) 0.733
No drinks/week 7,725 (76.0) 1
Insulin use (yes vs. no) 3,559 (35.0) 1.69 (1.36, 2.10) ,0.001
ACE inhibitor (yes vs. no) 5,397 (53.1) 1.18 (0.95, 1.47) 0.135
Angiotensin receptor blockers (yes vs. no) 1,618 (15.9) 0.67 (0.47, 0.95) 0.024
Statins (yes vs. no) 6,311 (62.1) 1.16 (0.93, 1.46) 0.194
Metformin (yes vs. no) 6,080 (59.8) 0.90 (0.73, 1.12) 0.360
Sulfonylureas (yes vs. no) 5,092 (50.1) 0.77 (0.62, 0.96) 0.021
Thiazolidinediones (yes vs. no) 1,967 (19.4) 0.76 (0.57, 1.03) 0.077
BMI (kg/m2) 32.2 6 5.5 1.01 (0.99, 1.03) 0.382
Systolic blood pressure (mmHg) 136.3 6 17.1 1.00 (1.00, 1.01) 0.365
Diastolic blood pressure (mmHg) 74.9 6 10.6 0.98 (0.97, 0.99) ,0.001
Visual acuity ,0.001
,20/40 2,310 (23.8) 3.22 (2.06, 5.04) ,0.001
20/20–20/40 5,906 (60.8) 1.97 (1.28, 3.04) 0.002
$20/20 1,502 (15.5) 1
Peripheral neuropathy (yes vs. no) 4,328 (42.7) 1.86 (1.49, 2.31) ,0.001
Heart rate 72.6 6 11.7 1.00 (0.99, 1.01) 0.847
Q-T index 101.7 6 5.2 1.06 (1.04, 1.07) ,0.001
A1C in % (mmol/mol) 8.3 6 1.1 (67 6 1) 1.19 (1.09, 1.31) ,0.001
Fasting plasma glucose (mg/dL) 175.3 6 56.2 1.00 (1.00, 1.00) 0.258
LDL (mg/dL) 104.9 6 33.9 1.00 (1.00, 1.00) 0.515
HDL (mg/dL) 41.8 6 11.6 0.98 (0.97, 0.99) ,0.001
Triglycerides (mg/dL) 190.3 6 148.7 1.00 (1.00, 1.00) 0.928
Serum creatinine (mg/dL) 0.9 6 0.2 4.04 (2.81, 5.82) ,0.001
Continued on p. 2003
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measureswere,2.2, tolerancemeasures
were .0.45, and condition index meas-
ures were,3.2; thus, we did not see col-
linearity as an issue in our analyses.
Comparisons of updated, average
insulin doses between the two interven-
tion groups were performed using two-
sample t tests. The association between
updated, average A1C and updated, aver-
age insulin dose (total, basal, and bolus)
was examined using linear regression
models (Fig. 1). For each type of insulin,
the updated, average insulin dosewas the
dependent variable and the updated, av-
erage A1C was the independent variable.
The treatment assignment was included
in the model. To check whether the asso-
ciation was the same in both treatment
assignment groups, we included an inter-
action between treatment assignment
and updated, average A1C.
A series of Cox proportional hazards
regression models was computed to ex-
plore the association between each cat-
egory of insulin and CV mortality (Table
2). Model 1 adjusted for the baseline
factors identified in the selection proce-
dures, with the exception of baseline in-
sulin use, since this variable would be
highly confounded with the initial dose
of insulin.Model 2 added indicators rep-
resenting assignment to either blood
pressure or lipid substudy groups and
within blood pressure/lipid substudy
treatment assignments, in addition to
time-dependent measures of severe hy-
poglycemia, and weight change. Model
3 added updated, average A1C as a time-
dependent covariate. Model 4 added
the variable representing glycemic
treatment assignment. Each model was
fit three times including a single up-
dated, average insulin variable at a
time (i.e., separatemodels for total insulin,
basal insulin, and bolus insulin) to explore
the association with CVmortality. Further-
more, interactions between each insulin
exposure and both duration of diabetes
(#10 years vs. .10 years) and baseline
history of CV disease were tested within
model 1, and the interactions between gly-
cemic treatment assignment and each in-
sulin exposure were tested using model 4.
For identification of which baseline
characteristics were most responsible
for the observed association between
CV mortality and insulin dose in the un-
adjusted model, an additional series of
Cox proportional hazards models was
fitted using three separate approaches.
HRs for total insulin dose were esti-
mated: 1) in the presence of each base-
line covariate by itself, 2) when the
covariate was the only potential con-
founder not included, and 3) based
on a stepwise approach that enters var-
iables based on the size of the P value.
For the stepwise approach, the con-
founding variable in model 1 that was
most significantly associated with CV
mortality was entered in the unadjusted
model, with the second most signifi-
cantly associated confounding variable
being subsequently entered and so
forth until the significance of the HR be-
tween CV mortality and insulin dose dis-
appeared (Supplementary Table 3).
For exploration of the linearity as-
sumption between updated, average
A1C and the insulin variables relative
to CV mortality, smoothing curves (pe-
nalized B-splines) were fitted to the re-
lationships over the range of updated,
average A1C levels and insulin variables
(Fig. 2). The curves were calculated
based on the linear portion of the Cox
proportional hazards models with full
covariate adjustment (model 4). Tests
of linearity of the effects of updated,
average A1C and insulin variables on
CV mortality were performed by com-
paring models containing linear terms
with those containing spline terms using
likelihood ratio tests. The linearity tests
were performed within each treat-
ment group. Tests of differences of the
nonlinear fits between two glycemic
treatment assignment groups were per-
formed by comparing the nested mod-
els with one spline (i.e., using the same
lines for both intervention groups) and
two splines (i.e., allowing different lines
within intervention groups) using a like-
lihood ratio test.
RESULTS
Baseline Characteristics and CV
Mortality
Our comparison between the baseline
characteristics of those prescribed insu-
lin postrandomization and those never
prescribed insulin (within intervention
groups) identified several statistically
significant differences between the
two groups in both arms (Supplemen-
tary Tables 1 and 2). Factors associated
with prescription of insulin during
ACCORD included, but were not limited
to, race/ethnicity, diabetes duration,
history of CV disease, smoking, diabetes-
related complications, the type of
health plan the participant was enrolled
in, and whether the site was led by an
endocrinologist or diabetologist rather
than another type of medical practi-
tioner. Thus, these results illustrate
some of the confounding between par-
ticipant characteristics and future pre-
scription of insulin.
There were 328 total CV deaths ob-
served in ACCORD (N = 10,163). Several
of the baseline characteristics were
Table 1—Continued
Baseline characteristic Value HR (95% CI) P Overall P
Urinary albumin-to-creatinine ratio (mg/mg) ,0.001
,30 6,937 (68.8) 1
30 to #300 2,481 (24.6) 1.96 (1.54, 2.49) ,0.001
.300 670 (6.6) 3.71 (2.73, 5.04) ,0.001
Integrated health plan (yes vs. no) 4,050 (39.9) 1.41 (1.13, 1.75) 0.002
Endocrinologist or diabetologist (either vs. other physician) 5,664 (55.7) 0.81 (0.65, 1.00) 0.052
Certified diabetes educator on staff at randomization 3,927 (38.6) 0.78 (0.62, 0.98) 0.030
Site size 0.978
,100 1,568 (15.4) 0.99 (0.72, 1.37) 0.969
100–150 3,027 (29.8) 1.02 (0.80, 1.31) 0.848
.150 5,568 (54.8) 1
Values are means 6 SD or n (%).
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associatedwith an increased risk ofCVmor-
tality in the univariate analysis (Table 1).
Those included older age; male sex; longer
duration of diabetes; previous history of
CVdisease,myocardial infarction, conges-
tive heart failure, and diabetes-related
complications; insulin use prior to ran-
domization; and higher A1C level, serum
creatinine, and urine albumin-to-creati-
nine ratio.
Insulin Exposure During Intensive
Versus Standard Treatment
More participants allocated to intensive
treatment (79%) than standard treat-
ment (62%) used insulin at some time
during follow-up. The mean 6 SD
(25th percentile, median, 75th percen-
tile) of the updated, average daily total
insulin dose for all participants in the in-
tensive arm (counting the dose in those
not using insulin as 0) was 0.41 6 0.43
units/kg body wt (0.03, 0.31, 0.65)
compared with 0.30 6 0.40 units/kg
Table 2—HRs (95% CI) and P values for CV mortality based on updated, average insulin dose (per 1 unit/kg) from Cox
proportional hazards models
Insulin categories Unadjusted Model 1 Model 2 Model 3 Model 4
Total insulin 1.83 (1.45, 2.31) ,0.001 1.21 (0.92, 1.60) 0.173 1.21 (0.91, 1.61) 0.191 1.12 (0.84, 1.49) 0.454 0.99 (0.74, 1.34) 0.969
Basal insulin 2.29 (1.62, 3.23) ,0.001 1.30 (0.87, 1.94) 0.207 1.29 (0.85, 1.95) 0.227 1.13 (0.74, 1.72) 0.564 0.94 (0.61, 1.46) 0.796
Bolus insulin 3.36 (2.00, 5.66) ,0.001 1.65 (0.88, 3.11) 0.117 1.63 (0.85, 3.12) 0.140 1.48 (0.77, 2.84) 0.237 1.23 (0.63, 2.40) 0.548
Model 1 adjusted for age, history of CV disease, heart failure, amputation, education, angiotensin receptor blockers, peripheral neuropathy, Q-T
index, baseline A1C, HDL, serum creatinine, urinary albumin-to-creatinine ratio, integrated health plan, and certified diabetes educator on
staff at randomization. Model 2 adds assignment to blood pressure or lipid trial and treatment assignment within these, severe hypoglycemia,
and weight change. Model 3 adds updated, average A1C. Model 4 adds glycemic treatment strategy assignment.
Figure 1—Smoothing curves for association between updated, average A1C (%) and updated, average total insulin dose (units/kg) for the two
treatment strategies over the range of average A1C from 6.0 to 9.0% (42 to 75 mmol/mol). The bold red line represents the intensive treatment
group, and the bold dashed blue line represents the standard group. The finer-colored lines represent the 95% CIs for each group. The association
between A1C level and insulin dose in the intensive group was marginally different compared with the association in the standard group (P for
interaction = 0.065). In the stratified analysis, an increase in updated, average A1C was associated with an increase in updated, average insulin dose
within each treatment group (regression coefficient estimates are 0.20 and 0.18 for the intensive group and the standard group, respectively; both
P , 0.001).
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body wt (0, 0.10, 0.53) in the standard
arm (P, 0.001). The corresponding values
for basal insulin were 0.30 6 0.29
units/kg body wt (0.02, 0.24, 0.46) vs.
0.22 6 0.28 units/kg body wt (0, 0.09,
0.38) (P , 0.001) and for bolus insulin
were 0.12 6 0.18 units/kg body wt
(0, 0.02, 0.18) vs. 0.08 6 0.17 units/kg
body wt (0, 0, 0.10) (P , 0.001).
Relationship Between Updated,
Average A1C and Updated, Average
Total Insulin Dose
The updated, average total insulin dose
increased linearly with increasing up-
dated, average A1C values in both treat-
ment arms (Fig. 1). At all A1C levels, the
mean total daily insulin dose in the in-
tensive treatment arm was higher than
in the standard treatment arm.
The association between A1C level and
insulin dose was not statistically different
between the two glycemic treatment
arms (P = 0.065). In the stratified analysis,
an increase in updated, average A1C was
associated with an increase in updated,
average insulin dose within each treat-
ment group (regression coefficient esti-
mates 0.20 and 0.18 for the intensive
group and the standard group, respec-
tively, both P , 0.001).
Association Between Insulin Dose and
CV Mortality With and Without
Adjustment for Baseline and
On-Treatment Characteristics
Results of the proportional hazards re-
gression models adjusting for the effects
of potentially confounding variables are
summarized in Table 2. Before adjustment
for covariates, a 1 unit/kg increase in av-
erage daily insulin dose was associated
with significant increases in risk of CV
death for all three categories of insulin
use (HR 1.83 [95% CI 1.45, 2.31] for total
insulin, 2.29 [1.62, 3.23] for basal insulin,
and 3.36 [2.00, 5.66] for bolus insulin).
After adjustment for baseline factors in
model 1, HRs were attenuated and no
longer statistically significant for all cate-
gories of insulin. Further adjustment for
treatment allocation in the blood pres-
sure and lipid components of ACCORD;
occurrence of severe hypoglycemia;
weight change; updated, average A1C;
and intensive versus standard treatment
assignment led to little further change in
these associations (models 2, 3, and 4). In
the fully adjusted model (model 4), the
HRs for associations of total, basal,
Figure 2—Spline curves displaying the risk of CV mortality with the two treatment strategies over the range of updated, average total insulin dose
(units/kg). The curves represent the linear part of the Cox proportional hazards models derived from values for updated, average total insulin from
model 4. The bold red line represents the intensive treatment group, the bold dashed blue line represents the standard group, and the finer-colored
lines represent the 95% CIs for each group. The reference group is for an updated, average total insulin of 0 in the standard group. There was no
evidence that the shape of the curves was statistically different between treatment groups (P for interaction = 0.358), and there was no evidence of
nonlinearity within each treatment group (intensive P = 0.375; standard P = 0.523) or evidence of a nonzero slope within groups (intensive P = 0.975;
standard P = 0.930).
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and prandial insulin exposure with CV
death were 0.99 (0.74, 1.34), 0.94 (0.61,
1.46), and 1.23 (0.63, 2.4), respectively.
Because most of the attenuation of the
unadjusted association between insulin
dose and CV mortality occurred after the
inclusionofonly thebaseline factors in the
multivariable model 1, we examined each
of the 14 baseline variables separately.
Both in the absence of other baseline co-
variates and as the last covariate adjusted
for, the greatest attenuation of the HR for
total insulin was after adjustment for a
history of congestive heart failure. With
use of a forward stepwise approach based
upon sequentially adding covariates with
the smallest P value, the greatest effect
was seen with adjustment for baseline
A1C, the presence of a history of conges-
tive heart failure, peripheral neuropathy,
and CV disease at baseline. Attenuation
of the associations with CV mortality oc-
curred similarly for total insulin, basal in-
sulin, andmealtime insulin (The results for
the total insulin dose are shown in Sup-
plementary Table 3).
Investigation of differential effects of
insulin dose on CV mortality within
baseline levels of duration of diabetes
indicated that we could not conclude
that the insulin effect was different
within levels (#10 years vs. .10 years)
of baseline duration of diabetes (inter-
action P values for total, basal, and bolus
insulin are P = 0.110, P = 0.205, and
P = 0.123). Similar results were found
for baseline CV history, where we found
that the interactions were not signifi-
cant for all the three insulin variables
(interaction P values for total, basal,
and bolus insulins are 0.876, 0.842,
and 0.794, respectively).
The spline results provide no evidence
that the shapes of the curves were statis-
tically different between treatment
groups (P = 0.358) (Fig. 2) and no evidence
of nonlinearity within each treatment
group (intensive P = 0.375; standard
P = 0.523) or evidence of a nonzero slope
within groups (intensive P = 0.975; stan-
dard P = 0.930). Assessment of basal
and bolus doses separately over the
observed dose ranges resulted in sim-
ilar findings.
Association Between Updated,
Average A1C and CV Mortality
As in prior analyses of all-cause mortal-
ity, higher updated, average A1C was
associated with higher CV mortality
both before (HR 1.38 [95% CI 1.22,
1.55], P , 0.001) and after (HR 1.49
[95% CI 1.30, 1.71], P , 0.001) adjust-
ment for updated, average total insulin
dose and other covariates listed in
model 4 of Table 2. The associations
were similar when updated, average
basal and bolus insulin were used (HR
1.50 and 1.48, respectively).
CONCLUSIONS
As previously reported, insulin was used
more often and at higher average doses
in the intensive arm of ACCORD than in
the standard arm. This was true for basal
and prandial insulin separately, as well
as for total daily insulin dose. These find-
ings were not unexpected, given the pol-
icy of the ACCORD study to escalate the
dose of insulin in order to attain the
lower A1C target.
Within each arm of the study, there
was a strong correlation between the
updated, average A1C and the dose of
insulin used (Fig. 1). It was also noted
that, for any A1C level, participants in
the intensive arm had a higher average
dose of insulin than those in the stan-
dard arm. This observation is consistent
with our expectation that individuals in
the intensive arm who were unable to
reduce A1C ,7% (53 mmol/mol) used
higher doses of injected insulin than
those in the standard arm.
Before adjustment for baseline char-
acteristics, which differed substantially
between participants using insulin and
those not using insulin, an increase in
daily insulin dose by 1 unit/kg body wt
was associated with a 1.8- to 3.4-fold
increase in hazard of CV death, support-
ing the possibility that the dose of in-
jected insulin used may have enhanced
CV risk. The unadjusted HRs were similar
to what has been observed in epidemi-
ological studies linking insulin exposure
with mortality (3,15).
However, after adjustment for the ef-
fects of baseline characteristics in the
multivariable model 1, insulin dose was
no longer significantly associated with
CV mortality. Additional models were
used to investigate on-treatment fac-
tors that could have possibly been re-
lated to both CV mortality and insulin
dose adjustments. Notably, in model 2,
which additionally adjusted for the
changeofweight andoccurrenceof severe
hypoglycemia, the relationship between
total insulin dose and CV mortality was
unchanged from that in model 1, which
only adjusted for baseline characteristics.
This absence of attenuation of risk pro-
vides no support for the hypothesis that
higher insulin doses lead to CV death by
causing severe hypoglycemia.
Model 3 had postrandomization A1C
levels added to model 2 because glyce-
mic control could be related to pre-
scribed insulin doses and also to severe
hypoglycemia or other potential media-
tors of risk. Finally, model 4 had the gly-
cemic treatment strategy assignment
added to model 3 in recognition that
there could be other features of the
treatment strategies used, beyond
those already included, that might influ-
ence outcomes. Adjustment for these
postrandomization covariates in models
3 and 4 provided further, albeit modest,
attenuation of the HRs, with confidence
limits ranging from at least a 26% reduc-
tion to at most a 34% increase in the
hazard associated with insulin use of
any type. For basal and bolus insulin,
the CIs are wider than for total insulin,
encompassing effects for a 1 unit/kg dif-
ference in insulin dose that range from
;40% reduction to a 250% increase in
the risk of CV mortality. Overall, conclu-
sions about the relationship between in-
sulin dose and CV death were little
affected by addition of the postrandom-
ization covariates, but the width of the
CIs calls attention to the need for cau-
tion in interpretation.
In a separate analysis, the baseline
characteristics that contributed the
most to the association between insulin
dose and CV death were baseline A1C,
history of congestive heart failure, pe-
ripheral neuropathy, and history of CV
disease (Supplementary Table 3). Nota-
bly, the distributions of these four cova-
riates were significantly different at
baseline in the subjects who used insulin
during the study versus those who did
not, regardless of their assignment to
the intensive versus standard treatment
groups (Supplementary Tables 1 and 2).
Clearly patients who used insulin dif-
fered from patients who did not use in-
sulin in their underlying risk of CV
mortality.
The results of these analyses, failing
to confirm an independent relationship
between insulin dose and CV mortality,
are consistent with the results of the
Outcome Reduction With Initial Glar-
gine Intervention (ORIGIN) trial in which
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participants were randomized to treat-
ment with basal insulin or to standard
oral step therapy as the basis for glycemic
management (22). No association be-
tween basal insulin use and CV risk was
found in the high–CV risk cohort studied
in ORIGIN, although the ORIGIN study
population had a much shorter duration
of diabetes or dysglycemia and less evi-
dence of microvascular complications of
diabetes than ACCORD participants.
The lack of harmful relationship be-
tween insulin dose and CV mortality in
our study is also consistent with what
was observed in the Diabetes Control
and Complications Trial (DCCT) and the
UK Prospective Diabetes Study (UKPDS).
In the DCCT/Epidemiology of Diabetes
Interventions and Complications (EDIC)
cohort, there were fewer CV events in
the intensive arm, where subjects re-
ceived higher insulin doses, than in the
conventional arm (23). Similarly, in the
UKPDS no increase in CV events was
found among individuals assigned to
treatment with insulin compared with
sulfonylurea or a conventional treat-
ment strategy based on lifestyle inter-
vention (24).
However, the present findings differ
to some extent from those in other re-
ports, where insulin was associated with
mortality (3,14–16). One reason for the
difference may be the quantity and
quality of data prospectively collected
during .3 years of follow-up of the
.10,000 participants in ACCORD, in-
cluding extensive information on both
the characteristics of the participants
at baseline and some on-treatment fac-
tors. In addition, we were able to model
details of prescribed insulin therapy, in-
cluding ever use, insulin dose, and insu-
lin type.
While recognizing these strengths of
this analysis, we also acknowledge the
limitations inherent in analyses of this
kind. One such limitation is the fact
that our study was a post hoc associa-
tional analysis. Therefore, the results
should be interpreted with caution ow-
ing to the well-known statistical and
other limitations of such analyses (25).
Another limitation is the issue of con-
founding by the clinician’s choices in
selecting therapies and doses, i.e., con-
founding by indication. Also, unmea-
sured covariates or confounders may
influence the vulnerability of a given in-
dividual to the effects of insulin. This
possibility is highlighted by the differ-
ences in the known clinical character-
istics at baseline in insulin-treated
participants (higher A1C and increased
prevalence of congestive heart failure,
peripheral neuropathy, and history of
CV disease), which suggest further but
unapparent differences in underlying
physiology or behavior that may relate
to CV risk. The possibility that patients
with these characteristics may, when
treated with high doses of insulin, be
more susceptible to mortality resulting
from hypoglycemia or some other
mechanism is an area that should be
further explored. Also, we did not at-
tempt to distinguish between the ef-
fects of different insulin molecules
(human vs. analogs) owing to limitations
of the data available.
In summary, in our analysis of
ACCORD data, average daily insulin
dose was not associated with increased
CV mortality after adjustment for base-
line covariates. These results fail to sup-
port the hypothesis that exposure to
injected insulin is an independent risk
factor for CV mortality in this popula-
tion. However, these exploratory analy-
ses of ACCORD do not fully lay to rest the
possibility of adverse effects of insulin in
particularly vulnerable individuals.
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